Mounjaro stopped working — what's really going on?

Six weeks in, the scale hasn't moved, here's what's probably happening

Picture this: the first two months on Mounjaro were encouraging. The appetite quietness was almost startling. Then, somewhere around the twelve-week mark, things slowed. The scale stopped moving. The hunger started creeping back slightly. It's easy to read this as the medicine giving up on you, but the biology tells a different story.

Tirzepatide, the active ingredient in Mounjaro, works by activating both GIP and GLP-1 receptors, slowing gastric emptying and reducing appetite signals. What the clinical-trial data also shows is that weight loss follows a curve: steeper early on, then flattening as the body reaches a new equilibrium at a given dose. In the SURMOUNT-1 trial, the largest and most sustained losses happened in participants who moved through the full titration schedule to higher doses. A plateau at 5mg or 7.5mg may simply mean the current dose has done what it can at that level, and progression is the clinical question to put to your prescriber.

There's also a less-discussed mechanism at play. As body weight falls, your resting energy expenditure falls with it, you need fewer calories to maintain a lower weight. Even with appetite suppression, the same intake that produced a deficit three months ago may now be roughly maintenance. This isn't a failure of the medicine; it's physiology. The NHS tirzepatide medicines page notes that treatment should always sit alongside a reduced-calorie diet and increased physical activity, because the medicine supports those changes rather than replacing them.

One thing worth checking honestly: has anything drifted? Portions, snack frequency, alcohol, movement. Nobody sets out to slip, but it happens gradually, often around busy patches at work, school holidays, or a run of weeks where Monday orders and good intentions fell away. A brief food and activity diary for a week, before your next clinical review, can reveal a lot.

When 'not working' might mean something more specific

There's an important distinction between a plateau (where weight has stabilised) and a complete loss of appetite suppression, where food feels appealing again in the way it did before treatment. Both are worth addressing, but they point to different things.

If the appetite-quietening effect has genuinely faded, some people describe this as happening in the final days before their next injection. That 'wear-off' feeling towards the end of the week is reported anecdotally and is worth flagging to your prescriber, it can influence timing discussions, though any adjustment to your injection schedule is a clinical decision, not something to make independently. If you're unsure whether what you're experiencing is a genuine plateau or something else, this guide on what to do when Mounjaro doesn't seem to be working walks through how to tell the difference.

Separately, if you've been at the same dose for more than eight weeks with no movement at all, that's the clearest signal to seek a clinical review. NICE's guidance on tirzepatide, published in December 2024, sets out that if someone achieves less than 5% weight loss after six months at their highest tolerated dose, continuing treatment should be reviewed. That threshold is a long-term clinical benchmark, not a short-term verdict, but it gives a sense of what 'not responding' means in formal terms. The NICE tirzepatide appraisal (TA1026) sets this out in detail.

There are also a small number of people for whom the medicine genuinely isn't well-suited, certain medical histories, other medicines, or conditions that affect absorption. Only a prescriber reviewing your full record can identify those factors. If you're wondering whether something more specific is at play with your response to treatment, the detailed clinical explainer on why Mounjaro may not be working covers the less obvious reasons.

What not to do while you wait for a review

The instinct when treatment seems to stall is to do something, skip a dose, take it more frequently, search for a higher strength online, or stop altogether. None of those responses is safe without clinical input, and some carry real risks.

Stopping Mounjaro abruptly after sustained use can cause appetite to return quickly and significantly. Clinical trial data shows that a meaningful proportion of weight lost on GLP-1 and dual-agonist medicines can return after stopping, the speed varies, but the pattern is consistent enough to be worth understanding before making that call. If you're concerned this might happen to you, understanding what happens when Mounjaro stops working and why can help you have a more informed conversation with your prescriber before you make any decisions. If cost is part of what's making you consider stopping, it's worth reading through what practical options exist when the monthly cost feels unsustainable before making a decision.

Sourcing a higher dose from an unverified seller carries its own dangers. The MHRA has issued repeated warnings about counterfeit tirzepatide pens circulating in the UK supply chain, some containing wrong substances entirely. The only safe route to any dose change is through a prescriber, dispensing from a pharmacy registered with the GPhC.

What you can reasonably do in the meantime: re-engage with the dietary and activity side of treatment, keep a record of what's changed, and book a clinical review. If you're at a dose that's been steady for several months and you want to understand whether a higher strength might be appropriate, that's exactly the kind of conversation a prescriber is there for. Our clinical team includes GPhC-registered Independent Prescribers who review every case personally (not a screening algorithm) and who can look at your progress and talk through the options. For broader context on what happens when progress seems to slow at specific doses, this detailed look at whether Mounjaro stops working over time, and what the evidence actually says is useful reading before your appointment.

If you'd like a prescriber to review your current treatment, the first step is a free consultation. Check your eligibility and start the process here.